低疾病活动度或缓解的类风湿关节炎患者动脉粥样硬化未见加速
该研究对139例非糖尿病类风湿关节炎(RA)患者(至少75%时间处于缓解/低疾病活动度,DAS28<3.2)与139名匹配对照进行3.2年随访,发现两组亚临床动脉粥样硬化指标变化无显著差异。使用生物制剂与传统合成DMARD的患者间动脉粥样硬化指标变化也相当。有效控制疾病可能消除RA对动脉粥样硬化进展的特异性影响。
要点
- RA患者若持续处于缓解/低疾病活动度,动脉粥样硬化进展与一般人群相当
- 生物制剂与传统合成DMARD对亚临床动脉粥样硬化进展的影响无显著差异
- 需前瞻性研究验证早期持续控制RA能否转化为预期的心血管结局
核心结论
- 有效控制疾病活动可能消除RA对动脉粥样硬化进展的任何特异性影响,且与抗风湿治疗方案无关。
研究设计与样本
- 连续入组的非糖尿病RA患者,此前接受超声检查评估亚临床动脉粥样硬化,在3.2(0.2)年后复评,前提是至少75%的时间处于缓解/低疾病活动度(DAS28<3.2)。
- 患者(n=139)与139名非糖尿病、非RA对照者在人口学上匹配,平行研究。
主要发现
- 患者与对照组基线平均年龄56岁,经典心血管疾病危险因素负担相当。
- 患者脉搏波速度(反映动脉僵硬度)变化为0.07 m/s/年,左侧颈动脉内中膜厚度(反映管壁肥厚)增加0.009 mm/年。
- 颈动脉和/或股动脉新发动脉粥样硬化斑块形成发生于22%的患者。
- 校正所有经典心血管疾病危险因素及降压/降脂治疗后,多因素分析显示患者与对照组在任何亚临床动脉粥样硬化指标上均无显著差异。
- 56例接受生物制剂DMARD治疗的患者与人口学匹配的接受合成DMARD治疗的患者相比,所有动脉粥样硬化指标从基线至随访结束的变化相当。
临床怎么用
- 对于达到并维持缓解/低疾病活动度的RA患者,无需因RA本身而过度担忧动脉粥样硬化加速进展。
- 临床应重视RA患者的疾病活动度控制,以可能消除RA对动脉粥样硬化的特异性影响。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: RA associates with increased cardiovascular disease (CVD) morbidity and mortality due to accelerated atherosclerosis, attributed to both classical risk factors and chronic inflammation. The aim of this study was to test the hypothesis that effective disease control over 3 years modifies acceleration of atherosclerosis in RA. METHODS: Consecutive, non-diabetic RA patients previously examined by ultrasonography for subclinical atherosclerosis were re-evaluated after 3.2 (0.2) years, provided that they were in remission/low disease activity (DAS28 <3.2) for at least 75% of this period. Patients (n = 139) were demographically matched with 139 non-diabetic, non-RA control individuals studied in parallel. RESULTS: Patients and controls (mean age of 56 years at baseline) had a comparable burden of classical CVD risk factors. Patients' pulse wave velocity (reflecting arterial stiffness) changed by 0.07 m/s/year and left carotid intima-media thickness (reflecting wall hypertrophy) increased by 0.009 mm/year; formation of new atheromatic plaques in carotid and/or femoral arterial beds occurred in 22%. Multivariate analysis after correcting for all classical CVD risk factors and anti-hypertensive/lipid-lowering therapies demonstrated no significant differences between patients and controls in any of the subclinical atherosclerosis indices. Changes in all atherosclerosis indices from baseline to end of follow-up were comparable between those 56 patients treated with biologic DMARDs and their demographically matched patients treated with synthetic DMARDs. CONCLUSION: Effective disease control may abrogate any RA-specific effect on the progression of atherosclerosis regardless of treatment. Whether early and sustained RA control translates to the CVD outcomes expected in the general population should be examined in prospective studies.
引用
- Arida A, Protogerou AD, Konstantonis G, et al. Atherosclerosis is not accelerated in rheumatoid arthritis of low activity or remission, regardless of antirheumatic treatment modalities. Rheumatology (Oxford). 2017. PMID: 28160488. doi:10.1093/rheumatology/kew506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。